MitoRx Therapeutics Announces Scientific Advisory Board, Chief Development Officer and Finance Director
March 07, 2023 03:00 ET
|
MitoRx Therapeutics
OXFORD, England, March 07, 2023 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a biotechnology company developing revolutionary therapeutics that reverse mitochondrial dysfunction to arrest the...
Guardion Launches Second Ocular Health Formula ‘GlaucoCetin’
June 04, 2019 07:00 ET
|
Guardion Health Sciences, Inc.
In an IRB-approved trial conducted at the New York Eye and Ear Infirmary, the parent compound of GlaucoCetin, GlaucoHealth, designed by Robert Ritch, MD, successfully reversed mitochondrial...